An evidence-based review of skin cancer rates on biologic therapies

Journal of Dermatological Treatment

Volumn 23, Issue 4, 2012, Pages 305-315

  Kamangar, Faranak ^a   Neuhaus, Isaac M ^b   Koo, John Y M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti TNF; Biologic; Cutaneous cancer; Psoriasis; Skin cancer

Indexed keywords

ADALIMUMAB; ALEFACEPT; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

ANKYLOSING SPONDYLITIS; BIOLOGICAL THERAPY; CANCER RISK; CANCER THERAPY; CROHN DISEASE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MERKEL CELL TUMOR; META ANALYSIS (TOPIC); NON MELANOMA SKIN CANCER; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; SKIN CANCER; SYSTEMATIC REVIEW;

BIOLOGICAL AGENTS; HIDRADENITIS SUPPURATIVA; HUMANS; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SKIN NEOPLASMS;

EID: 84863941161     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2011.652064     Document Type: Review

References (60)

1. Fernandez-Vozmediano JM, Armario-Hita JC. Infliximab for the treatment of hidradenitis suppurativa. Dermatology. 2007; 215:41-44.
2. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: SECTION 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58: 851-864.
3. Castelo-Soccio L VVA. Long-term efficacy of biologics in dermatology. Dermatol Ther. 2009;22:22-33.
4. Menter A. The effect of psoriasis on patients' quality of life and improvements associated with alefacept therapy. J Cutan Med Surg. 2004;8(Suppl 2):20-25.
5. Katugampola RP, Lewis VJ, Finlay AY. The Dermatology Life Quality Index: Assessing the efficacy of biological therapies for psoriasis. Br J Dermatol. 2007;156:945-950.
6. Gisondi P, Girolomoni G. Biologic therapies in psoriasis: A new therapeutic approach. Autoimmun Rev. 2007;6: 515-519.
7. Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: Meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. 2011;20: 119-130.
8. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64:1421-1426.
9. Wolfe F,Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study. Arthritis Rheum. 2007;56:2886-2895.
10. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, et al. Cancer risk in the Swiss HIV Cohort Study: Associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97:425-432.
11. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348:1681-1691.
12. Hannuksela-Svahn A, Pukkala E, Laara E, Poikolainen K, Karvonen J. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol. 2000;114:587-590.
13. Naldi L. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: Facts and controversies. Clin Dermatol. 2010;28:88-92.
14. Koo JL, Lee C, Lebwohl M, Weinstein G, Gottlieb A. Moderate-to-Severe Psoriasis, 3rd ed. New York: INFORMA Healthcare; 2009.
15. Enbrel. (Etanercept). Prescribing information. Manufactured by Immunex Corporation. Marketed by Amgen Inc. and Pfizer Inc. Updated 2011.
16. Lebwohl M, Blum R, Berkowitz E, Kim D, Zitnik R, Osteen C, et al. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 Years. Arch Dermatol. 2005: 861-864.
17. Gottlieb AB, Gordon K, Giannini EH, Mease P, Li J, Chon Y, et al. Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications. J Drugs Dermatol. 2011;10:289-300.
18. Praiser DM LC, Gordon K, leonardi CL, Gottlieb K, Tyring S, Papp KA, et al. Short and Long-term safety profiles of etanercept in patients with psoriasis: An integrated analysis. Poster Presented at: 66th annual meeting of the American Academy of Dermatology; Poster 2618. San Antonio, Tx. 2008.
19. Harris RB, Griffith K, Moon TE. Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996. J Am Acad Dermatol. 2001;45:528-536.
20. Gray DT, Suman VJ, Su WP, Clay RP, Harmsen WS, Roenigk RK. Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Arch Dermatol. 1997;133:735-740.
21. Gottlieb AB, Leonardi CL, Goffe BS, Ortonne JP, Van Der Kerkhof PC, Zitnik R, et al. Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy database. J Am Acad Dermatol. 2006; 54(3 Suppl 2):S92-S100.
22. Ly L, Czarnecki D. The rapid onset of multiple squamous cell carcinomas during etanercept treatment for psoriasis. Br J Dermatol. 2007;157:1076-1078.
23. Lafaille P, Bouffard D, Provost N. Exacerbation of undiagnosed mycosis fungoides during treatment with etanercept. Arch Dermatol. 2009;145:94-95.
24. Chuang GS, Wasserman DI, Byers HR, Demierre MF. Hypopigmented T-cell dyscrasia evolving to hypopigmented mycosis fungoides during etanercept therapy. J Am Acad Dermatol. 2008;59(5 Suppl):S121-S122.
25. (Humira). Prescribing information. North Chicago, IL: ABBOTT Laboratories; 2011.
26. Burmester GR, Mease P, Dijkmans BA, Gordon K, Lovell D, Panaccione R, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis. 2009;68: 1863-1869.
27. Scotto J FT, Fraumeni JF Jr. Incidenc of non-melanoma skin cancer in the United States. Pub no (NIH) 82-2433. Bethesda, MD: us Department of Health and Human Services, Public Health Service, NIH, NCI; 1981.
28. kerdel FTD, Blauvelt A, Abramovits W, Langley R, Poulin Y, Papp K, et al. Esprit: INTERIM Results from a 10-year postmarketing surveillance registry for Adalimumab treatment for moderate to severe psoriasis. 69th annual meeting of American Academy of Dermatology. New Orleans Louisiana. 2011.
29. Krishna SM, Kim CN. Merkel cell carcinoma in a patient treated with adalimumab: Case report. Cutis. 2011; 87:81-84.
30. Dalle S, Balme B, Berger F, Hayette S, Thomas L. Mycosis fungoides-associated follicular mucinosis under adalimumab. Br J Dermatol. 2005;153:207-208.
31. Remicade (Infliximab) prescribing information, 1st ed. Centocor, Inc. PDR; 2010.
32. Chakravarty EF, MichaudK,Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol. 2005;32:2130-2135.
33. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: Meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009;68: 1136-1145.
34. Fulchiero GJ Jr. Salvaggio H, Drabick JJ, Staveley- O'Carroll K, Billingsley EM, Marks JC, et al. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol. 2007;56(5 Suppl): s65-S67.
35. Katoulis AC, Kanelleas A, Zambacos G, Panayiotides I, Stavrianeas NG. Development of two primary malignant melanomas after treatment with adalimumab: A case report and review of the possible link between biological therapy with TNF-alpha antagonists and melanocytic proliferation. Dermatology. 2010;221:9-12.
36. Kowalzick L, Eickenscheidt L, Komar M, Schaarschmidt E. Long term treatment of psoriasis with TNF-alpha antagonists. Occurrence of malignant melanoma. Hautarzt. 2009;60: 655-657.
37. Amevive (Alefacept) Prescribing information, 1st ed. Astellas, Inc. PDR; 2010.
38. krell J BJ, Coynik D. Assessment and tracking of long termalefacept safety (ATLAS): Analysis of data from approximately 1,200 patients [abstract]. J Am Acad Dermatol. 2007;56 (2 Suppl 2): ab191.
39. Leonardi CL, Toth D, Cather JC, Langley RG, Werther W, Compton P, et al. A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology. 2006;213:204-214.
40. Stelara. (ustekinumab) prescribing information, Centocor, Inc. Revised October 2010.
41. Papp K HV, Yeilding N, Gordon N, Szapary P, Li S, Kreuger G, et al. Maligancies in ustekinumab-treated psoriasis patients: Observations with up to 3 years of follow-up and comparisons to the general US population [poster]. Society of Investigative Dermatology Annual Meeting. Atlanta, Goergia. 2010.
42. Reich K LC, Griffiths CEM, Szapary PO, WAsfi Y, Hsu MC, Gordon K. Update on the cumulative safety experience of ustekinumab: Results from the ustekinumab psoriasis clinical development program with up to 4 years of follow-up. 22nd World Congress of Dermatology. Seoul, Korea. 2011.
43. van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: Molecular insights, antitumor effects, and clinical utility. Oncologist. 2006;11:397-408.
44. Marmenout A, Fransen L, Tavernier J, Van Der Heyden J, Tizard R, Kawashima E, et al. Molecular cloning and expression of human tumor necrosis factor and comparison with mouse tumor necrosis factor. Eur J Biochem. 1985;152:515-522.
45. Lejeune FJ, Ruegg C, Lienard D. Clinical applications of TNF-alpha in cancer. Curr Opin Immunol. 1998;10: 573-580
46. Muller U, Jongeneel CV, Nedospasov SA, Lindahl KF, Steinmetz M. Tumour necrosis factor and lymphotoxin genes map close to H-2D in the mouse major histocompatibility complex. Nature. 1987;325:265-267.
47. Bemelmans MH, van Tits LJ, Buurman WA. Tumor necrosis factor: Function, release and clearance. Crit Rev Immunol. 1996;16:1-11.
48. Muppidi JR, Tschopp J, Siegel RM. Life and death decisions: Secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity. 2004;21:461-465.
49. Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 2006;25:409-416.
50. Malik ST, Griffin DB, Fiers W, Balkwill FR. Paradoxical effects of tumour necrosis factor in experimental ovarian cancer. Int J Cancer. 1989;44:918-925.
51. Orosz P, Echtenacher B, Falk W, Ruschoff J, Weber D, Mannel DN. Enhancement of experimental metastasis by tumor necrosis factor. J Exp Med. 1993;177:1391-1398.
52. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, et al. IL-23 promotes tumour incidence and growth. Nature. 2006;442:461-465.
53. Maeda A, Schneider SW, Kojima M, Beissert S, Schwarz T, Schwarz A. Enhanced photocarcinogenesis in interleukin-12- deficient mice. Cancer Res. 2006;66:2962-2969.
54. Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: A 5 y cohort study. J Invest Dermatol. 2003;120:211-216.
55. Penn I. Post-transplant malignancy: The role of immunosuppression. Drug Saf. 2000;23:101-113.
56. Nelson RP Jr. Ballow M. 26. Immunomodulation and immunotherapy: Drugs, cytokines, cytokine receptors, and antibodies. J Allergy Clin Immunol. 2003;111(2 Suppl): s720-S743. 314 F. Kamangar et al.
57. Penn I. Overview of the problem of cancer in organ transplant recipients. Ann Transplant. 1997;2:5-6.
58. Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman J, Ewigman B, et al. Strength of recommendation taxonomy (SORT): A patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract. 2004;17: 59-67.
59. Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol. 2001;45:953-956.
60. Robinson JK, Dellavalle RP, Bigby M, Callen JP. Systematic reviews: Grading recommendations and evidence quality. Arch Dermatol. 2008;144:97-99.